Literature DB >> 30165077

CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity.

Chris G Parsons1.   

Abstract

Drug repurposing is recently gaining increasing attention, not just from pharmaceutical companies but also from government agencies in an attempt to generate new medications to address increasing unmet medical needs in a cost effective and expedite manner. There are several approaches to identify novel indications for known drugs. Many are based on rational selection e.g. the known or a new mechanism of action of a drug. This review will focus rather on phenotypic or high content screening of compounds in models that are believed to be predictive of effectiveness of compounds irrespective of their mechanism of action. Three short cases studies of screens for Alzheimer's disease, Parkinson's disease and spasticity will be given as examples. This article is part of the Special Issue entitled 'Drug Repurposing: old molecules, new ways to fast track drug discovery and development for CNS disorders'.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Drug repurposing; High content screen; Parkinson's disease; Phenotypic; Repositioning; Spasticity; α-synuclein; β-amyloid

Mesh:

Year:  2018        PMID: 30165077     DOI: 10.1016/j.neuropharm.2018.08.027

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

Review 1.  Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents.

Authors:  Sha Zhu; Qifeng Bai; Lanqing Li; Tingyang Xu
Journal:  Comput Struct Biotechnol J       Date:  2022-06-01       Impact factor: 6.155

2.  A Study to Decipher the Potential Effects of Butylphthalide against Central Nervous System Diseases Based on Network Pharmacology and Molecular Docking Integration Strategy.

Authors:  Qinqin Zhao; Bei Zheng; Pinpin Feng; Xiang Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-04       Impact factor: 2.629

Review 3.  Repositioning of drugs for Parkinson's disease and pharmaceutical nanotechnology tools for their optimization.

Authors:  Héctor Hernández-Parra; Hernán Cortés; José Arturo Avalos-Fuentes; María Del Prado-Audelo; Benjamín Florán; Gerardo Leyva-Gómez; Javad Sharifi-Rad; William C Cho
Journal:  J Nanobiotechnology       Date:  2022-09-15       Impact factor: 9.429

4.  Repurposed agents in the Alzheimer's disease drug development pipeline.

Authors:  Justin Bauzon; Garam Lee; Jeffrey Cummings
Journal:  Alzheimers Res Ther       Date:  2020-08-17       Impact factor: 6.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.